Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence
Reads0
Chats0
TLDR
It is argued that montelukast should be further tested to prevent and treat COVID-19 outcomes, based on gathered theoretical evidence.Abstract:
With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the present article was to review the properties of montelukast that could be beneficial in COVID-19. Ten experimentally supported properties were retrieved, either related to SARS-CoV-2 (antiviral properties, prevention of endotheliitis and of neurological disorders linked to SARS-CoV-2), and/or related to the host (improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms), and/or related to serious COVID-19 outcomes (limitation of the cytokine storm, mitigation of acute respiratory distress syndrome), and/or related to tissue sequelae (antioxidant properties, anti-fibrosis effects). Based on gathered theoretical evidence, we argue that montelukast should be further tested to prevent and treat COVID-19 outcomes.read more
Citations
More filters
Journal ArticleDOI
Mast cell activation symptoms are prevalent in Long-COVID.
Leonard B. Weinstock,Jill B Brook,Arthur S. Walters,Ashleigh J. Goris,Lawrence B. Afrin,Gerhard J. Molderings +5 more
TL;DR: In this paper, the authors determined prevalence/severity of MCA symptoms in Long-COVID (LC) patients and found that increased activation of aberrant mast cells induced by SARS-CoV2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy.
Journal ArticleDOI
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
Hayder M Al-Kuraishy,Ali I Al-Gareeb,Yaaser Q. Almulaiky,Natália Cruz-Martins,Gaber El-Saber Batiha +4 more
TL;DR: In this paper, the potential role of leukotrienes (LTs) in the pathogenesis and clinical presentation of SARS-CoV-2 infection, and reveal the critical role of LT pathway receptor antagonists and inhibitors in Covid-19 management.
Journal ArticleDOI
Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.
Sugandh Kumar,Sugandh Kumar,Bharati Singh,Bharati Singh,Pratima Kumari,Preethy V. Kumar,Preethy V. Kumar,Geetanjali Agnihotri,Shaheerah Khan,Tushar K. Beuria,Gulam Hussain Syed,Anshuman Dixit +11 more
TL;DR: In this paper, the authors used bioinformatics techniques to screen the FDA approved drugs against nine SARS-CoV2 proteins to identify drugs for repurposing and analyzed if the identified molecules can also affect the human proteins whose expression in lung changed during SARS CoV2 infection.
Journal ArticleDOI
In silico validation of anti-viral drugs obtained from marine sources as a potential target against SARS-CoV-2 Mpro
TL;DR: In this article, a total of 14 marine derived antiviral agents were screened from several databases including PubChem and DrugBank and docked against the crystallised 3D structure of SARS-CoV-2 Mpro.
Journal ArticleDOI
The Pathophysiology of Long COVID throughout the Renin-Angiotensin System
Shaymaa H. Khazaal,Julien Harb,Mohamad Rima,Cédric Annweiler,Yingliang Wu,Zhijian Cao,Z. Abi Khattar,Christian Legros,Hervé Kovacic,Ziad Fajloun,Jean-Marc Sabatier +10 more
TL;DR: The impact of long COVID on several organs and tissues is summarized, with a special focus on the significance of the RAS in the disease pathogenesis.
References
More filters
Journal ArticleDOI
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.
Ling Mao,Huijuan Jin,Mengdie Wang,Yu Hu,Shengcai Chen,Quan-Wei He,Jiang Chang,Candong Hong,Yifan Zhou,David Z. Wang,Xiaoping Miao,Yanan Li,Bo Hu +12 more
TL;DR: During the epidemic period of COVID-19, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.
Journal ArticleDOI
Endothelial cell infection and endotheliitis in COVID-19.
Zsuzsanna Varga,Andreas J. Flammer,Peter Steiger,Martina Haberecker,Rea Andermatt,Annelies S. Zinkernagel,Mandeep R. Mehra,Reto A. Schuepbach,Frank Ruschitzka,Holger Moch +9 more
TL;DR: The vascular endothelium is an active paracrine, endocrine, and Endothelial cell infection and endotheliitis in COVID-19 and recruitment of immune cells can result in widespread endothelial dysfunction associated with apoptosis.
Journal ArticleDOI
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Frederikus A. Klok,Marieke J. H. A. Kruip,N.J.M. van der Meer,M.S. Arbous,Diederik Gommers,K.M. Kant,F H J Kaptein,J. van Paassen,M A M Stals,Menno V. Huisman,Henrik Endeman +10 more
TL;DR: The findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophYLaxis towards high-prophylactic doses, even in the absence of randomized evidence.
Journal ArticleDOI
Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment
TL;DR: The Berlin definition of acute respiratory distress syndrome addressed limitations of the American-European Consensus Conference definition, but poor reliability of some criteria may contribute to underrecognition by clinicians.
Journal ArticleDOI
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza.
Alexander E Merkler,Neal S. Parikh,Saad Mir,Ajay Gupta,Hooman Kamel,Eaton Lin,Joshua E Lantos,Edward J. Schenck,Parag Goyal,Samuel S. Bruce,Joshua Kahan,Kelsey N Lansdale,Natalie M LeMoss,Santosh B. Murthy,Philip E. Stieg,Matthew E. Fink,Costantino Iadecola,Alan Z. Segal,Marika M. Cusick,Thomas R. Campion,Iván Díaz,Cenai Zhang,Babak B. Navi +22 more
TL;DR: Almost 1.6% of adults with COVID-19 who visited the emergency department or were hospitalized experienced ischemic stroke, a higher rate of stroke compared with a cohort of patients with influenza, and the association persisted across sensitivity analyses adjusting for vascular risk factors, viral symptomatology, and intensive care unit admission.